Zobrazeno 1 - 10
of 912
pro vyhledávání: '"Eslicarbazepine acetate"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe approval of eslicarbazepine acetate (ESL) by the Food and Drug Administration (FDA) in 2013 marked an advancement in the treatment of adult patients with partial-onset seizures. However, there still remains a paucity of real-world studi
Externí odkaz:
https://doaj.org/article/2f7dcfba14e842dfa08a260a6cc5f1f0
Autor:
Rumyana Kuzmanova, I. Vaneva
Publikováno v:
Българска неврология, Vol 25, Iss 1 (2024)
Епилепсията е едно от най-честите неврологични заболявания и засяга приблизително 70 милиона души по света. Лечението на епилепсията е п
Externí odkaz:
https://doaj.org/article/0a517c6f1b3348ed956ed3c8a78bba6f
Autor:
Jaime Gonçalves-Sánchez, Thomas Ramírez-Santos, Dolores E. López, Jesús M. Gonçalves-Estella, Consuelo Sancho
Publikováno v:
Biomedicines, Vol 12, Iss 5, p 1121 (2024)
Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug indicated as monotherapy for adults with newly diagnosed epilepsy and as adjunctive therapy for the treatment of partial seizures. Our aim was to assess the effectiveness and safe
Externí odkaz:
https://doaj.org/article/d6ab939b11914d378f1ed301471ab34e
Autor:
Hamada Altalib, Todd Grinnell, David Cantu, Fábio Ikedo, Mariana Vieira, Yi Zhang, David Blum
Publikováno v:
Epilepsia Open, Vol 7, Iss 4, Pp 616-632 (2022)
Abstract Objective Eslicarbazepine acetate (ESL) is a once‐daily (QD), oral anti‐seizure medication for the treatment of focal (partial‐onset) seizures. Here, we evaluate risk factors for the development of psychiatric treatment‐emergent adve
Externí odkaz:
https://doaj.org/article/d3026b02cce5409bb9490b2ea2f5cf9d
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 16, Pp 4091-4099 (2022)
Ping Liu,1,2 Jing An,2 Huizhen Wu1,2 1Graduate School of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei General Hospital, Shijiazhuang, People’s Republi
Externí odkaz:
https://doaj.org/article/be26f0ed74e743b29484ea252753d8c2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Eslicarbazepine acetate, a third-generation antiepileptic drug (AED), has shown improved clinical response and safety in comparison to older generation AEDs for patients with partial-onset seizures. It is currently not known whether eslicarbazepine a
Externí odkaz:
https://doaj.org/article/7bd8e5f27e1e47b09717a79a9102f91c
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundThe efficacy and tolerability of eslicarbazepine acetate (ESL) in adults and children with focal-onset epilepsy (FOE) according to the dose remain to be validated. A meta-analysis based on randomized controlled trials (RCTs) was therefore c
Externí odkaz:
https://doaj.org/article/4720ca7e2d90482683bf42666719f849
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 13, Pp 251-261 (2021)
Darshan Mehta,1 Matthew Davis,2 Andrew J Epstein,3 Brian Wensel,1 Todd Grinnell,4 G Rhys Williams1 1Sunovion Pharmaceuticals Inc., Marlborough, MA, USA; 2Medicus Economics, LLC, Milton, MA, USA; 3Medicus Economics, LLC, Philadelphia, PA, USA; 4Medica
Externí odkaz:
https://doaj.org/article/19860c1bb9fe45bda6f7ea2116130952
Autor:
Darshan Mehta, Matthew Davis, Andrew J. Epstein, Brian Wensel, Todd Grinnell, G. Rhys Williams
Publikováno v:
Neurology and Therapy, Vol 9, Iss 2, Pp 585-598 (2020)
Abstract Introduction This study assessed the association between early initiation of eslicarbazepine acetate (ESL) as first-line therapy (1L cohort) or as first adjunctive regimen to either levetiracetam (LEV) or lamotrigine (LTG) (add-on cohort), a
Externí odkaz:
https://doaj.org/article/47842719762544ec9d431ab8dfd0d800